Coronavirus Update:What patients and families need to know
The Children's National Research Institute
Patient-Specific Tissue Engineered Vascular Graft System
Researchers at Children's National Hospital have developed a system to customize vascular grafts to overcome any complications such as incompatibility, obstruction and infections.
Congenital heart disease (CHD) is the leading cause of death in newborns with congenital abnormalities. According to CDC, about 40,000 infants or 1% of births are affected by CHD, and about 25% of them may require invasive surgeries. The single ventricle anomalies (SVAs), one of the largest groups of CHDs have a 70% mortality rate. The SVA and other CHD surgeries involve complications such as obstruction, lack of growth potential to accommodate the needs of a growing child, increased susceptibility to infection, and increased risk of thromboembolism. Furthermore, these grafts have high failure rates (70-100%) within a 10-15 year period requiring subsequent replacement. Our innovative system is anticipated to overcome these problems with the following advantages:
- Patient-specific grafts.
- Reduced risk of obstruction.
- Low risk of incompatibility with vascular grafts.
- Low risk of infection and thromboembolism after introduction of graft.
- Applicable to pediatric and adult vascular grafts
Stage of Development
- Animal (sheep) studies performed. Preclinical studies ongoing.
Intellectual Property Status
- Pending U.S. Patent application “Patient-Specific Tissue Engineered Vascular Graft Utilizing Electrospinning”
This technology is available for exclusive or non-exclusive licensing.
Licensing/Business ContactSangeetha Raghavan
Senior Licensing Associate